Mbrx stock float

Why Investors Need To Watch Moleculin Biotech, Inc. (MBRX ... Mar 18, 2020 · MBRX currently has a short float of 1.59% and public float of 46.32M with average trading volume of 712.61K shares. MBRX Market Performance. MBRX stocks went down by -7.95% for the week, with the monthly drop of -31.57% and a quarterly performance of -49.01%, while its annual performance rate touched -58.39%. The stock volatility was left

Get Stock & Bond Quotes, Trade Prices, Charts, Financials and Company News & Information for OTCQX, OTCQB and Pink Securities. MBRX: Moleculin Biotech, Inc. - Zacks Investment Research MBRX: Moleculin Biotech, Inc. - Full Company Report. Get the latest Full Company Report for Moleculin Biotech, Inc. from Zacks Investment Research NASDAQ:MBRX Moleculin Biotech, Inc. Stock Analysis ...

Looking Into What Made Moleculin Biotech, Inc. (MBRX) Sink ...

Stock analysis for Moleculin Biotech Inc (MBRX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Did You Miss Your Chance to Buy Moleculin Biotech, Inc ... Mar 18, 2020 · Moleculin Biotech, Inc. (NASDAQ:MBRX) increased by 29.99%, which means its valuation on the stock-market now stands at $29.77M. Its share price closed at $0.52, having traded in a uptrend. Similarly, significant improvements in trading activity saw average volumes at the ready counter rise to 15,263,567 shares. Moleculin Biotech Inc. (MBRX) picks momentum as shares ... Mar 18, 2020 · 30 institutions hold shares in Moleculin Biotech Inc. (MBRX), with 5.94M shares held by insiders accounting for 12.99% while institutional investors hold 26.26% of the company’s shares. The shares outstanding are 57.23M, and float is at 46.32M with …

OTC Markets | MBRX

Company profile for Moleculin Biotech CS (MBRX) including business summary, key statistics, ratios, sector. Float, K: Shares a company has issued that are available to trade (shares outstanding - restricted stock). % Float: The percentage of regular shares available to trade. Growth Table. MBRX Stock Price, Forecast & News (Moleculin Biotech) Moleculin Biotech's stock was trading at $0.5051 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MBRX shares have increased by 12.8% and is now trading at $0.57. Moleculin Biotech Stock Quote. MBRX - Stock Price, News ...

Apr 03, 2020 · Stock quote and company snapshot for MOLECULIN BIOTECH INC (MBRX), including profile, stock chart, recent news and events, analyst opinions, and research reports.

Short Interest Stock Short Selling Data, Shorts, Stocks ... The mission of ShortSqueeze.com™ is to provide short interest stock market data and services, so our members will be better informed of short selling in the market, track shorts in stocks and gain from the advantages that can be achieved from this valuable market data.

Mar 3, 2020 Moleculin Biotech, Inc. (MBRX) company overview, trading data, share statistics, Shares Outstanding (Company), 53.23M Float %, 71.18% 

The shorts are running away from Moleculin Biotech, Inc. (MBRX) stock. The latest set of short interest data was released on 29 March 2019, and the numbers show a drop in short interest in MBRX shares. While short interest still represents only 4.68% of MBRX’s float, … Moleculin Biotech Inc. [MBRX] fell -43.16% so far this ... The market cap for MBRX stock reached $29.77 million, with 57.23 million shares outstanding and 46.32 million shares in the current float. Compared to the average trading volume of 712.61K shares, MBRX reached a trading volume of 15263567 in the most recent trading day, which is why market watchdogs consider the stock to be active. Nasdaq Stock Market | Stock Quotes & Stock ... - Nasdaq Watch Get the latest stock market news, stock information & quotes, data analysis reports, as well as a general overview of the market landscape from Nasdaq. MBRX -- Is Its Stock Price A Worthy Investment? Learn More. Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company was founded in 2015 and is based in Houston, Texas.

NASDAQ:MBRX Moleculin Biotech, Inc. Stock Analysis ... Moleculin Biotech, Inc. is a preclinical and clinical-stage, pharmaceutical company, which focused on the development of anti-cancer drug candidates. Moleculin Biotech (MBRX): 22M share super low float runner!